Fig. 1.

Percentage of patients achieving PASI 75, PASI 90, PASI 100, and sPGA 0 or 1 at the most efficacious phase III dosage for each drug, at week 12, among the three AMAGINE trials.

Disclaimer: Data were tabulated from independent studies that were not conducted in a head-to-head manner. PASI Psoriasis Area and Severity Index, Q2W Every 2 weeks, sPGA Static Physician Global Assessment